Stigmasterol (C29 Phytosterol · Cholesterol-lowering · Anti-osteoarthritic · Steroid Precursor)

Compound	Stigmasterol
Chemical class	Terpenoid — Phytosterol (C29 plant sterol; 4-desmethyl sterol)
CAS	83-48-7
Primary source	Soybean oil, rapeseed oil, Glycine max; also in legumes, nuts, and widely distributed in plant foods
Key applications	Cholesterol-lowering; anti-inflammatory; hormone biosynthesis precursor; antiosteoarthritic
Claim strength	Moderate
Typical form	Natural phytosterol 95% powder (phytosterol blend containing stigmasterol, beta-sitosterol, campesterol)
Buy from Herbuno	Natural Phytosterol 95% Powder →

Name origin: From Stigma (referring to the stigmata/stigmas of Physostigma venenosum, the Calabar bean from which stigmasterol was first characterised alongside physostigmine). Stigmasterol is a C29 phytosterol — its structure is essentially that of beta-sitosterol with an additional double bond at C-22 and an ethyl group at C-24. This makes stigmasterol more unsaturated than beta-sitosterol, which affects its membrane properties and pharmacological profile. Phytosterols as a class are structural analogues of cholesterol found in plant cell membranes — they competitively inhibit cholesterol absorption in the small intestine by displacing dietary cholesterol from mixed micelles, reducing serum LDL without affecting HDL. Traditional use: Dietary phytosterol consumption has a rich traditional food context — diets rich in plant foods (legumes, nuts, whole grains, vegetables) naturally provide 200–400 mg/day phytosterols vs Western diets at 150–400 mg/day. The Mediterranean diet’s cardiovascular benefit is partly attributed to higher phytosterol intake. The commercial phytosterol supplement and food fortification market arose from the 1990s discovery that 2g/day supplemental phytosterols reduces LDL by 10–15% — now FDA-approved for a cardiovascular disease risk reduction claim. Commercial source: Natural Phytosterol 95% Powder which delivers a blend of phytosterols including stigmasterol, beta-sitosterol, and campesterol is available from Herbuno.

---

Evidence for Stigmasterol Applications

Cholesterol-lowering — phytosterol class evidence (High): Stigmasterol contributes to the well-established phytosterol mechanism of LDL reduction: competitive displacement of dietary cholesterol from intestinal micelles, reducing cholesterol absorption by 30–50% and lowering LDL cholesterol by 10–15% at 2g/day total phytosterols. EFSA and FDA recognise phytosterol claims for cardiovascular risk reduction. Most clinical trial evidence uses phytosterol blends (not stigmasterol specifically), but stigmasterol contributes to the blend’s LDL-lowering effect. Claim strength: High (phytosterol class); Moderate (stigmasterol-specific).

Anti-inflammatory: Stigmasterol inhibits NF-κB and COX-2, reduces IL-1β and TNF-α in macrophage models. In osteoarthritis animal models, stigmasterol specifically has been shown to reduce articular cartilage degradation by inhibiting matrix metalloproteinase (MMP) expression — an effect not seen with beta-sitosterol or campesterol, suggesting stigmasterol-specific anti-osteoarthritic activity. Claim strength: Moderate.

Pharmaceutical hormone precursor: Stigmasterol is an important pharmaceutical raw material — used as starting material for the industrial synthesis of progesterone, cortisone, and other steroid hormones. The C-22 double bond of stigmasterol is chemically useful for introducing the specific side chain modifications required in steroid hormone synthesis. Most pharmaceutical steroid production begins from phytosterol raw materials (stigmasterol, beta-sitosterol, campesterol). Industrial/pharmaceutical reference.

---

Frequently Asked Questions — Stigmasterol

How much phytosterol does the average diet provide?
Dietary phytosterol intake varies significantly with dietary pattern: Western omnivore diet: 150–400 mg/day; vegetarian diet: 300–500 mg/day; Mediterranean diet: 400–600 mg/day; traditional Asian rice-based diet: 300–500 mg/day. The LDL-lowering effect of supplemental phytosterols (2g/day) adds approximately 1,500–1,800 mg on top of dietary intake. To achieve the clinically effective 2g/day dose entirely from diet would require consuming approximately 1 kg of whole grain products or 500g of nuts daily — not practical, explaining the market for phytosterol-enriched margarine and supplement products.

Are phytosterols safe for people with sitosterolaemia?
Sitosterolaemia (phytosterolaemia) is a rare autosomal recessive disorder (ABCG5/G8 mutations) causing massive intestinal hyperabsorption of dietary phytosterols including sitosterol and stigmasterol. Normal individuals absorb only 5–10% of dietary phytosterols; sitosterolaemia patients absorb 15–60%, causing tendon xanthomas, premature atherosclerosis, and haemolytic anaemia. Phytosterol supplementation is absolutely contraindicated in sitosterolaemia patients. For the general population, normal phytosterol absorption rates mean that supplemental phytosterol use does not cause meaningful plasma phytosterol accumulation.

Why is stigmasterol used to make progesterone pharmaceutically?
Stigmasterol’s C-22 double bond in the side chain allows ozonolysis (specific double bond cleavage) to produce C-21 steroid intermediates that can be efficiently converted to progesterone, cortisone, and other steroid hormones. Before the 1940s Marker synthesis from Mexican yam (diosgenin), steroid hormones were produced in tiny quantities at enormous cost. The Marker synthesis revolutionised steroid hormone manufacturing — and phytosterols including stigmasterol from soy oil became the primary pharmaceutical steroid precursor feedstocks from the 1950s onwards.

Is stigmasterol different from beta-sitosterol?
Both are C29 phytosterols differing by one additional double bond (C-22,23) in stigmasterol vs beta-sitosterol. For cholesterol-lowering, the LDL-reduction mechanism is essentially the same (intestinal micelle competition). For anti-inflammatory activity, stigmasterol appears to have more potent and specific anti-osteoarthritic effects than beta-sitosterol (inhibiting cartilage-degrading MMPs more specifically). For pharmaceutical synthesis, stigmasterol’s C-22 double bond makes it preferred over beta-sitosterol for certain steroid synthesis routes. In commercial phytosterol blends, stigmasterol is typically a minor fraction alongside beta-sitosterol.

Related compounds: Campesterol, Beta-Sitosterol, Charantin, Lupeol

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery